UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients

The Annals of pharmacotherapy, 2012-12, Vol.46 (12), p.1645

2012

Volltextzugriff (PDF)

Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer

Breast cancer research and treatment, 2016-04, Vol.156 (2), p.237-247

2016

Volltextzugriff (PDF)

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)

Breast (Edinburgh), 2017-10, Vol.35, p.203-217

2017

Volltextzugriff (PDF)

Effect of breast tumor subtype and site of distant metastatic disease on prognostic outcome among patients with brain metastases and stage IV denovo breast cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1034-1034

2018

Volltextzugriff (PDF)

Hope, bias and survival expectations of advanced cancer patients: A cross‐sectional study

Psycho-oncology (Chichester, England), 2021-05, Vol.30 (5), p.780-788

2021

Volltextzugriff (PDF)

The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women

Laboratory investigation, 2024-03, Vol.104 (3), p.100303-100303, Article 100303

2024

Volltextzugriff (PDF)

Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression

Modern pathology, 2023-04, Vol.36 (4), p.100056-100056, Article 100056

2023

Volltextzugriff (PDF)

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.503-503

2022

Volltextzugriff (PDF)

Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS1113-TPS1113

2019

Volltextzugriff (PDF)

Effect of progesterone receptor on outcome of women with breast cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.573-573

2016

Volltextzugriff (PDF)

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial

JAMA oncology, 2017-11, Vol.3 (11), p.1538

2017

Volltextzugriff (PDF)

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS602-TPS602

2018

Volltextzugriff (PDF)

Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence

Breast cancer research and treatment, 2019-11, Vol.178 (2), p.295-305

2019

Volltextzugriff (PDF)

The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach

Virchows Archiv : an international journal of pathology, 2019-12, Vol.475 (6), p.709-725

2019

Volltextzugriff (PDF)

An ASCO leadership development project to understand barriers to clinical cancer research in the Asia-Pacific

JCO global oncology, 2023-08, Vol.9 (Supplement_1), p.96-96

2023

Volltextzugriff (PDF)

Association of male breast cancer and prostate cancer: A large population based study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.1541-1541

2016

Volltextzugriff (PDF)

Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.515-515

2019

Volltextzugriff (PDF)

Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer

Journal of clinical oncology, 2014-09, Vol.32 (26_suppl), p.108-108

2014

Volltextzugriff (PDF)

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.153-162

2014

Volltextzugriff (PDF)

What is the role of immunotherapy in breast cancer?

Chinese Clinical Oncology, 2018-04, Vol.7 (2), p.13-13

2018

Volltextzugriff (PDF)

Impact of locoregional therapy among women 70 years or older with early stage hormone receptor positive breast cancer: A population based study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.573-573

2015

Volltextzugriff (PDF)

Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010-2011

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e12075-e12075

2015

Volltextzugriff (PDF)

Clinicopathological characteristics and treatment outcomes in patients with stage I-III invasive lobular carcinoma of the breast (ILC) treated at the National Cancer Centre Singapore

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e12005-e12005

2016

Volltextzugriff (PDF)

LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1009-1009

2017

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients

Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)

Effect of breast tumor subtype and site of distant metastatic disease on prognostic outcome among patients with brain metastases and stage IV denovo breast cancer

Hope, bias and survival expectations of advanced cancer patients: A cross‐sectional study

The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522

Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC)

Effect of progesterone receptor on outcome of women with breast cancer

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)

Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence

The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach

An ASCO leadership development project to understand barriers to clinical cancer research in the Asia-Pacific

Association of male breast cancer and prostate cancer: A large population based study

Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer

Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

What is the role of immunotherapy in breast cancer?

Impact of locoregional therapy among women 70 years or older with early stage hormone receptor positive breast cancer: A population based study

Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010-2011

Clinicopathological characteristics and treatment outcomes in patients with stage I-III invasive lobular carcinoma of the breast (ILC) treated at the National Cancer Centre Singapore

LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC)

Suchergebnisse filtern